PMID- 33197916
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1423-0267 (Electronic)
IS  - 0030-3755 (Linking)
VI  - 244
IP  - 2
DP  - 2021
TI  - Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of 
      Neovascular Age-Related Macular Degeneration.
PG  - 93-101
LID - 10.1159/000513048 [doi]
AB  - BACKGROUND: Despite the success of anti-vascular endothelial growth factors 
      (anti-VEGFs), currently, there is a need for highly effective compounds that can 
      alleviate the burden of managing neovascular age-related macular degeneration 
      (nAMD). PURPOSE: To review the milestones in the molecular and clinical 
      development of brolucizumab, the first single-chain antibody fragment (scFv) 
      designed specifically for intraocular use in humans. METHODS: In this article, we 
      summarize the preclinical and current clinical evidence of brolucizumab 
      administration with an overview of the other treatment regimens and additional 
      indications under investigation. RESULTS: The unique molecular design of 
      brolucizumab led to a low molecular weight of only 26 kDa, allowing for a 
      concentrated molar dose of 1 intravitreal injection compared with other anti-VEGF 
      agents. Phase I and II clinical trial outcomes validated the efficacy of 
      brolucizumab in the treatment of nAMD with signals of a more durable treatment 
      effect. The pivotal phase III trials, HAWK and HARRIER, which included a total of 
      1,817 patients, established that brolucizumab can be administered every 3 months 
      while maintaining disease control. CONCLUSIONS: The preclinical and clinical data 
      on brolucizumab provide evidence of sustained disease control with longer 
      injection intervals, thus potentially reducing the treatment burden in patients 
      with nAMD.
CI  - (c) 2021 S. Karger AG, Basel.
FAU - Tadayoni, Ramin
AU  - Tadayoni R
AD  - Universite de Paris, Ophthalmology Department, AP-HP, Hopital Lariboisiere, 
      Paris, France.
FAU - Sararols, Laura
AU  - Sararols L
AD  - Hospital General de Catalunya, Barcelona, Spain.
FAU - Weissgerber, Georges
AU  - Weissgerber G
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Verma, Rohini
AU  - Verma R
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Clemens, Andreas
AU  - Clemens A
AD  - Novartis Pharma AG, Basel, Switzerland, andreas.clemens@novartis.com.
AD  - Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, 
      University of Freiburg, Freiburg, Germany, andreas.clemens@novartis.com.
FAU - Holz, Frank G
AU  - Holz FG
AD  - Department of Ophthalmology, University of Bonn, Bonn, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201116
PL  - Switzerland
TA  - Ophthalmologica
JT  - Ophthalmologica. Journal international d'ophtalmologie. International journal of 
      ophthalmology. Zeitschrift fur Augenheilkunde
JID - 0054655
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - XSZ53G39H5 (brolucizumab)
SB  - IM
MH  - *Angiogenesis Inhibitors/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Humans
MH  - Intravitreal Injections
MH  - *Macular Degeneration/drug therapy
OTO - NOTNLM
OT  - Anti-VEGF
OT  - Brolucizumab
OT  - Neovascular age-related macular degeneration (AMD)
OT  - Single-chain antibody fragment
EDAT- 2020/11/17 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/11/16 20:17
PHST- 2020/06/11 00:00 [received]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/11/16 20:17 [entrez]
AID - 000513048 [pii]
AID - 10.1159/000513048 [doi]
PST - ppublish
SO  - Ophthalmologica. 2021;244(2):93-101. doi: 10.1159/000513048. Epub 2020 Nov 16.